Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

What’s new in chemotherapy for non-small cell lung cancer?

What’s new in chemotherapy for non-small cell lung cancer? Summary The last few years have seen an explosion of novel treatment options for patients diagnosed with lung cancer, mostly for those with stage IV non-small cell lung cancer. On the one hand, this was due to the development of modern diagnostic tools permitting accurate molecular diagnoses leading to the identification of several oncogenic driver mutations which can be therapeutically targeted. On the other hand, the advent of immunotherapy in medical oncology in general, but in thoracic oncology in particular, has changed the treatment landscape first in second-line systemic treatment, but recently also in first-line treatment in patients with programmed death ligand-1 (PD-L1) expression in their tumors of >50%. Despite those advances, the majority of patients we treat in our daily routine will still receive chemotherapy: a so-called druggable aberration is only found in approximately 20% of cases. Some 25% present with an activating KRAS mutation, which despite decades of research still cannot be directly targeted. In the remainder, no genomic aberration of direct clinical consequences has been identified. On the other hand, the rate of PD-L1 positivity >50% at diagnosis has been reported to be between 24.9 and 30.2%. Overall, this leaves the majority of patients without any of those options in first-line therapy and they will receive standard of care chemotherapy. This minireview discusses the latest developments in the field of chemotherapy for non-small cell lung cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

What’s new in chemotherapy for non-small cell lung cancer?

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/what-s-new-in-chemotherapy-for-non-small-cell-lung-cancer-9936ECi5q8
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0355-z
Publisher site
See Article on Publisher Site

Abstract

Summary The last few years have seen an explosion of novel treatment options for patients diagnosed with lung cancer, mostly for those with stage IV non-small cell lung cancer. On the one hand, this was due to the development of modern diagnostic tools permitting accurate molecular diagnoses leading to the identification of several oncogenic driver mutations which can be therapeutically targeted. On the other hand, the advent of immunotherapy in medical oncology in general, but in thoracic oncology in particular, has changed the treatment landscape first in second-line systemic treatment, but recently also in first-line treatment in patients with programmed death ligand-1 (PD-L1) expression in their tumors of >50%. Despite those advances, the majority of patients we treat in our daily routine will still receive chemotherapy: a so-called druggable aberration is only found in approximately 20% of cases. Some 25% present with an activating KRAS mutation, which despite decades of research still cannot be directly targeted. In the remainder, no genomic aberration of direct clinical consequences has been identified. On the other hand, the rate of PD-L1 positivity >50% at diagnosis has been reported to be between 24.9 and 30.2%. Overall, this leaves the majority of patients without any of those options in first-line therapy and they will receive standard of care chemotherapy. This minireview discusses the latest developments in the field of chemotherapy for non-small cell lung cancer.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Sep 1, 2017

References

  • Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra
  • Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    J Vansteenkiste, D Ruysscher, WE Eberhardt, E Lim, S Senan, E Felip
  • Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
    JY Douillard, R Rosell, M Lena, F Carpagnano, R Ramlau, JL Gonzales-Larriba
  • Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
    T Winton, R Livingston, D Johnson, J Rigas, M Johnston, C Butts
  • Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
    JP Pignon, H Tribodet, GV Scagliotti, JY Douillard, FA Shepherd, RJ Stephens
  • Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
    GV Scagliotti, P Parikh, J Pawel, B Biesma, J Vansteenkiste, C Manegold
  • Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study
    M Kreuter, J Vansteenkiste, JR Fischer, W Eberhardt, H Zabeck, J Kollmeier
  • A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer
    G Schmid-Bindert, W Engel-Riedel, M Reck, W Schuette, J Stohlmacher, JR Fischer
  • PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer
    S Senan, A Brade, LH Wang, J Vansteenkiste, S Dakhil, B Biesma
  • Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
    R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip
  • Crizotinib in ROS1-rearranged non-small-cell lung cancer
    AT Shaw, SH Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia
  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer
    BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail
  • Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
    M Mancini, Y Yarden
  • Comprehensive molecular profiling of lung adenocarcinoma
  • Pembrolizumab for the treatment of non-small-cell lung cancer
    EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder
  • Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
    M Reck, D Rodriguez-Abreu, AG Robinson, R Hui, T Csoszi, A Fulop
  • Nivolumab versus cocetaxel in advanced Nonsquamous non-small-cell lung cancer
    H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready
  • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    J Brahmer, KL Reckamp, P Baas, L Crino, WE Eberhardt, E Poddubskaya
  • PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
    LG Paz-Ares, F Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli
  • Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial
    MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, I Okamoto
  • Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
    CJ Langer, SM Gadgeel, H Borghaei, VA Papadimitrakopoulou, A Patnaik, SF Powell
  • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    A Sandler, R Gray, MC Perry, J Brahmer, JH Schiller, A Dowlati
  • Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
    M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski
  • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
    EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel
  • Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options
    S Popat, A Mellemgaard, M Reck, C Hastedt, I Griebsch
  • Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    N Thatcher, FR Hirsch, AV Luft, A Szczesna, TE Ciuleanu, M Dediu
  • 91PD_PRResponse to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
    SI Rothschild, P Leger, EL Castellanos, RN Pillai, SJ York, L Horn
  • Trastuzumab emtansine for HER2-positive advanced breast cancer
    S Verma, D Miles, L Gianni, IE Krop, M Welslau, J Baselga
  • Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC)
    T Stinchcombe, RA Stahel, L Bubendorf, P Bonomi, AE Villegas, D Kowalski